Multiple Rising Does Study (Subcutaneous Doses) of BI 655064 in Male and Female Patients With Chronic Primary Immune Thrombocytopenic Purpura (ITP).



Status:Completed
Conditions:Hematology, Hematology, Hematology
Therapuetic Areas:Hematology
Healthy:No
Age Range:18 - Any
Updated:5/5/2016
Start Date:December 2013
End Date:April 2016

Use our guide to learn which trials are right for you!

Trial Summary
Trial Overview
Inclusion Criteria

Safety, Efficacy, Tolerability, Pharmacokinetics and Pharmacodynamics of Open Label Study With Multiple (and for Non Responders) Escalating Subcutaneous Doses of BI 655064 Once a Week in Patients With Chronic Primary Immune Thrombocytopenic Purpura.

BI 655064 will be administered subcutaneously once weekly in patients with immune
thrombocytopenic purpura (ITP) for up to 12 weeks.


Inclusion criteria:

Male and female chronic immune ITP patients

Exclusion criteria:

Any treatment of ITP excluded except for a stable dose of corticosteroids (up to 20 mg)
We found this trial at
2
sites
Boehringer Ingelheim Investigational Site
Los Angeles, California
?
mi
from
Los Angeles, CA
Click here to add this to my saved trials
Boehringer Ingelheim Investigational Site
New York, New York
?
mi
from
New York, NY
Click here to add this to my saved trials